CUREMETRIX APPOINTS LISA WATANABE, M.D. AS CHIEF MEDICAL OFFICER

LA JOLLA, CA, USA, May 30, 2018 /EINPresswire.com/ -- CureMetrix®, a San Diego-based software company that is leveraging artificial intelligence and deep machine learning to develop the next generation of medical image analysis technology to assist radiologists in detecting key regions of interest and quantifying and classifying anomalies on a mammogram, today announced the appointment of Lisa Watanabe, M.D. as Chief Medical Officer. Dr. Watanabe succeeds the late Dr. Bill Bradley, the former CMO of CureMetrix, who passed away late last year.

Dr. Lisa Watanabe, newly appointed Chief Medical Officer of CureMetrix

"Lisa brings over 20 years of clinical experience as an accomplished and well-esteemed radiologist to our team. We've benefitted from her guidance during her time as our Clinical Research Director, but as we have gained momentum with our investigational products, we now need the focus of a highly qualified CMO with an extensive global network, deep business acumen and a passion to positively impact a radiologist's workflow and ultimately improve patient outcomes," said Chief Executive Officer, Kevin Harris.

> Lisa brings over 20 years of clinical experience as an accomplished and well-esteemed radiologist to our team."
> *Kevin Harris, CEO CureMetrix*

Dr. Watanabe currently holds a position as Clinical Associate Professor at University of Southern California, Keck School of Medicine in the neuroradiology division. She served as past President of the American Society of Spine Radiology in 2006 and is currently a California Councilor to the American College of Radiology and on the Executive Committee of the California Radiological Society. She has lectured extensively at society meetings in neuroradiology and breast imaging and her articles have been published in numerous peer-reviewed medical journals including the American Journal of Radiology, the American Journal of Neuroradiology and Radiology. In addition, Dr. Watanabe is a reviewer for numerous medical journals and an Expert Reviewer for the California Medical Board.

Dr. Watanabe graduated Phi Beta Kappa from Stanford University and was a Regents Scholar at

University of San Francisco Medical School. Dr. Watanabe did her neuroradiology fellowship training at the University of Washington and University of Southern California and then served as a Clinical Instructor of Radiology at USC's Keck School of Medicine. She is a Senior Member of the American Society of Neuroradiology and holds the Certificate of Added Qualification (CAQ) from the American Board of Radiology. She is the past Director of Breast Imaging at Patricia Scheifly Breast Center at Presbyterian Intercommunity Hospital and the Women's Wellness Center at the Little Company of Mary Hospital.

Dr. Watanabe (front row, left) with CureMetrix team

Over the last two years, Dr. Watanabe presented scientific abstracts and was invited to lecture at numerous meetings including RSNA, ECR, ASSR and SBI on the application of artificial intelligence-based software for medical imaging. She has also been involved in the CureMetrix cmAssist® mammography CAD installations in Mexico and in research partnerships with multiple institutions including MD Anderson Cancer Center and Johns Hopkins Medical Center. In her new role, Dr. Watanabe will be responsible for developing and executing on the Company's medical strategy and clinical development plans to successfully drive CureMetrix next-generation medical image analysis technology into hospitals and clinics globally.

To learn more about Dr. Lisa Watanabe and the CureMetrix leadership team, please visit our website.

About CureMetrix
CureMetrix® was founded in 2014 on the belief that better medical image analysis technology could lead to better outcomes for breast cancer patients. The company is developing investigational, physics-based artificial intelligence and deep learning solutions to help radiologists achieve more accurate readings of breast images. Through its research partnerships with leading hospital radiology departments, CureMetrix has evaluated more than 500,000 mammogram images to identify potential false negatives, which are undiagnosed cancers, and false positives, which are unnecessary recalls of patients to review anomalies that turn out to be normal. False negatives can occur at a rate of about one in five breast cancers.1 False positives affect 7-12 percent of all women after an initial mammogram.2 Reducing false positives could save a significant portion of the $4 billion per year spent on unneeded and sometimes invasive procedures such as biopsies.3 More importantly, reducing false negatives could save lives as well as reduce the cost and difficulty of cancer treatment through early detection.

Our goal is to create CAD that Works®. Improving computer-aided detection through a robust physics-based algorithm for detecting cancer empowers radiologists, supports their patients and reduces costs while improving clinical outcomes. To learn more about CureMetrix, visit www.curemetrix.com.

1 https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html
2 http://ww5.komen.org/BreastCancer/AccuracyofMammograms.html
3 http://content.healthaffairs.org/content/34/4/576.abstract

Elise Crispen
CureMetrix
6198578212
email us here
